JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

Maria Kleppe, Minsuk Kwak, Priya Koppikar, +20

Cancer Discovery

JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer

Adrian Britschgi, Rita Andraos, Heike Brinkhaus, +6

Cancer Cell

Metastatic Breast CancerSignaling PathwayBreast OncologyPi3k/mtor BlockadeMedicine +8

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird, +28

The Journal of Experimental Medicine

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms

Sara C. Meyer, Matthew D. Keller, Sophia Chiu, +35

Cancer Cell

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia

Shuo-Chieh Wu, Loretta S. Li, Nadja Kopp, +38

Cancer Cell

Hematological MalignancyMixed-phenotype Acute LeukemiaMalignant Blood DisorderImmunologyHematology +4

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis, +20

Molecular Cancer Therapeutics

Cell DeathPi3k Inhibitor Nvp-bkm120Cancer BiologyTumor BiologyMicrotubule Dynamics +23

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, +28

Nature Cancer

Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers

Stéphane Ferretti, Jacques Hamon, Ruben de Kanter, +33

Nature

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, +24

Cancer Research

JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease

Emeline Evrot, Nicolas Ebel, Vincent Romanet, +11

Clinical Cancer Research